BriaCell Reports CD80 Variant With Over 130-Fold Stronger PD-L1 Binding
BriaCell and majority-owned BriaPro announced four preclinical presentations at SITC 2026. One engineered CD80 variant showed 0.23 µM PD-L1 binding versus more than 30 µM for wild-type; Bria-OTS+ immune activity was reported in lab models across breast, prostate and lung cancers.